Gut 2001;48:816-820 ( June )

Article

Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998 S D Taylor-Robinson^a, M B Toledano^b, S Arora^b, T J Keegan^b, S Hargreaves^c, A Beck^d, S A Khan^a, P Elliott^b, H C Thomas^a

^a Liver Unit, Department of Medicine A, Imperial College School of Medicine, St Mary's Campus, South Wharf Street, London W2 1PG, UK, ^b Department of Epidemiology and Public Health, Imperial College School of Medicine, St Mary's Campus, South Wharf Street, London W2 1PG, UK, ^c Kensington and Chelsea and Westminster Health Authority, 50, Eastbourne Terrace, London W2 6LX, UK, ^d Department of Biological Sciences, Wye College, University of London, Wye, Ashford, Kent TN25 5AH, UK

Correspondence to: Dr S D Taylor-Robinson, Liver Unit, Department of Medicine A, 10th Floor, QEQM Wing, Imperial College School of Medicine, St Mary's Hospital, South Wharf Street, London W2 1PG, UK. s.taylor-robinson{at}ic.ac.uk

Accepted for publication 19 December 2000

BACKGROUNDThe age standardised mortality rate per 100 000 population for all causes of liver tumours (International Classification of Disease 9 (ICD-9) 155) has almost doubled in England and Wales during the period 1979-1996. We further analysed the mortality statistics to determine which anatomical subcategories were involved.
METHODSMortality statistics for liver tumours of ICD-9 155, 156, and subcategories, and for tumours of the pancreas (ICD-9 157), in England and Wales were investigated from the Office for National Statistics, London, from 1968 to 1996 inclusive. Data for 1997 and 1998 were also available on intrahepatic cholangiocarcinomas.
RESULTSThere has been a marked rise in age standardised mortality rates for intrahepatic cholangiocarcinoma. Since 1993, it represents the commonest recorded cause of liver tumour related death in England and Wales. This is evident in age groups older than 45 years. In contrast, mortality trends from other primary liver tumours, including hepatocellular carcinoma, were unremarkable.
CONCLUSIONSThe observed increase in mortality from intrahepatic cholangiocarcinoma may represent better case ascertainment and diagnosis due to improved diagnostic imaging, use of image guided biopsies, or increased use of ERCP. However, the trend started before ERCP was introduced nationally, mortality rates have continued to increase steadily thereafter, and there is no clear evidence that diagnostic transfers easily explains the findings. Alternatively, these observations may represent a true increase in intrahepatic bile duct tumours. Epidemiological studies are required to determine whether there is any geographical clustering of cases around the UK.


Keywords: intrahepatic cholangiocarcinoma; age standardised mortality rates; age specific mortality rates

---

© 2001 by Gut
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Small fry starting to make waves

M ALISON
Gut 2001 48: 754-755. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• HASSID, V. J., ORLANDO, F. A., AWAD, Z. T., TAN, D., KHOURY, T., AHMED, B. H., ALRAWI, S. J. (2009). Genetic and Molecular Abnormalities in Cholangiocarcinogenesis. Anticancer Res 29: 1151-1156 [Abstract] [Full Text]  
• Pisani, P., Whary, M. T., Nilsson, I., Sriamporn, S., Wadstrom, T., Fox, J. G., Ljungh, A., Forman, D. (2008). Cross-Reactivity between Immune Responses to Helicobacter bilis and Helicobacter pylori in a Population in Thailand at High Risk of Developing Cholangiocarcinoma. CVI 15: 1363-1368 [Abstract] [Full Text]  
• Khan, S A, Miras, A, Pelling, M, Taylor-Robinson, S D (2007). Cholangiocarcinoma and its management. Gut 56: 1755-1756 [Full Text]  
• Williams, J G, Roberts, S E, Ali, M F, Cheung, W Y, Cohen, D R, Demery, G, Edwards, A, Greer, M, Hellier, M D, Hutchings, H A, Ip, B, Longo, M F, Russell, I T, Snooks, H A, Williams, J C (2007). Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut 56: 1-113 [Full Text]  
• Taniai, M., Grambihler, A., Higuchi, H., Werneburg, N., Bronk, S. F., Farrugia, D. J., Kaufmann, S. H., Gores, G. J. (2004). Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells. Cancer Res. 64: 3517-3524 [Abstract] [Full Text]  
• Tannapfel, A, Sommerer, F, Benicke, M, Katalinic, A, Uhlmann, D, Witzigmann, H, Hauss, J, Wittekind, C (2003). Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706-712 [Abstract] [Full Text]  
• Khan, S A, Carmichael, P L, Taylor-Robinson, S D, Habib, N, Thomas, H C (2003). DNA adducts, detected by 32P postlabelling, in human cholangiocarcinoma. Gut 52: 586-591 [Abstract] [Full Text]  
• Lai, G.-H., Zhang, Z., Sirica, A. E. (2003). Celecoxib Acts in a Cyclooxygenase-2-independent Manner and in Synergy with Emodin to Suppress Rat Cholangiocarcinoma Growth in Vitro through a Mechanism Involving Enhanced Akt Inactivation and Increased Activation of Caspases-9 and -3. Molecular Cancer Therapeutics 2: 265-271 [Abstract] [Full Text]  
• Khan, S A, Davidson, B R, Goldin, R, Pereira, S P, Rosenberg, W M C, Taylor-Robinson, S D, Thillainayagam, A V, Thomas, H C, Thursz, M R, Wasan, H (2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51: vi1-9 [Full Text]  
• Bettschart, V, Clayton, R A E, Parks, R W, Garden, O J, Bellamy, C O C (2002). Cholangiocarcinoma arising after biliary-enteric drainage procedures for benign disease. Gut 51: 128-129 [Full Text]  
• ALISON, M (2001). Small fry starting to make waves. Gut 48: 754-755 [Full Text]